MN-166 has a well-documented safety profile with low toxicity. It is generally well-tolerated, though mild gastrointestinal symptoms and fatigue may occur. No unexpected adverse effects have been reported in glioblastoma or ALS clinical trials.
[2,"smw-datavalue-wikipage-property-invalid-title","Has clinical trial explanation","In glioblastoma, a Phase 1b\/2a trial evaluated MN-166 in combination with temozolomide (TMZ), showing it was safe and well-tolerated. Progression-Free Survival at 6 months (PFS6) was 44% in newly diagnosed patients and 31% in recurrent cases, with the latter improving over historical controls. MN-166 is also in a Phase 2b\/3 trial for ALS (COMBAT-ALS), where interim analysis suggests it may slow disease progression. The trial is ongoing, with top-line data expected in 2026."]
[2,"smw-datavalue-wikipage-property-invalid-title","Has Usefulness Explanation","MN-166 shows promise in glioblastoma when combined with temozolomide, with clinical trials indicating improved progression-free survival. It has demonstrated potential in slowing neurodegenerative disease progression (ALS, MS, DCM) and is undergoing further clinical validation."]